Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Slides:



Advertisements
Similar presentations
Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,
Advertisements

Su K. Metcalfe, MD, MPH, Michael T
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
Electronic Updates for JTO Readers
Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu.
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer  Boris Sepesi, MD, Kathryn A. Gold, MD,
Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Frank Detterbeck, MD  Journal of Thoracic Oncology 
Influence of Apoptosis and Cell Cycle Regulator Proteins on Chemotherapy Response and Survival in Stage IIIA/IIIB NSCLC Patients  José L. Morero, MD,
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  J Noble,
Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer  Masahiko Harada,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Good Vibrations and the Power of Positron Thinking: Positron Emission Tomography and Endoscopic Ultrasound in Staging of Mesothelioma—Two Case Reports 
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer  Charles M. Rudin, MD, PhD,
The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition  Sai-Hong.
Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base  Kathryn E. Engelhardt,
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.
Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy  Naomi E. Verstegen,
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.
Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel  Makoto Kawaishi, MD, Yutaka Fujiwara, MD,
Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated.
Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome  Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.
Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.
Goulnar Kasymjanova, MD, José A
Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early- Stage Non–Small-Cell Lung Cancer: Combined Analysis of Two IFCT Randomized.
Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy  Sophie Papa, MRCP, PhD, Sanjay Popat, FRCP,
Immune-Modulating Vaccines in Non-small Cell Lung Cancer
Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada  Marcy Winget, PhD, Jennifer.
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value 
Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.
Ethnic Differences in the Management of Lung Cancer in New Zealand
Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J
Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Causes and Consequences of Deviation from Multidisciplinary Care in Thoracic Oncology  Raymond U. Osarogiagbon, MBBS, Gregory Phelps, MD, Joshua McFarlane,
Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.
Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:
Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients  Barbara S. van der Meij,
A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.
Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD 
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.
Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases  Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,
Presentation transcript:

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival  Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc, PhD, Alison Norton, MA, Sanjay Popat, MRCP, PhD, Sarah Hughes, MRCP, Panagiotous Papadopoulos, MD, Kathryn Priest, MSc, Mary O'Brien, MRCP, MD  Journal of Thoracic Oncology  Volume 2, Issue 8, Pages 735-740 (August 2007) DOI: 10.1097/JTO.0b013e31811f3a7d Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Consort diagram of patient denominator. PR, partial response; SD, stable disease; chemo, chemotherapy, NA, not assessed; PD, progressive disease. Journal of Thoracic Oncology 2007 2, 735-740DOI: (10.1097/JTO.0b013e31811f3a7d) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Log rank comparison of overall survival of patients based on response after two courses (PR2PR4: those with a partial response (PR) after two courses who continued to have a PR after four courses; SD2PR4: those with stable disease (SD) after two courses and attained a PR after four courses; SD2SD4: those with SD after two courses who continued to have SD after four courses). NSCLC, non-small cell lung cancer. Journal of Thoracic Oncology 2007 2, 735-740DOI: (10.1097/JTO.0b013e31811f3a7d) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Log rank comparison of overall survival adjusted for stage and sex based on response after two courses. PR, partial response; SD, stable disease. Journal of Thoracic Oncology 2007 2, 735-740DOI: (10.1097/JTO.0b013e31811f3a7d) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions